Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study

Nicola Richardson-Harman, Craig W Hendrix, Namandjé N Bumpus, Christine Mauck, Ross D Cranston, Kuo Yang, Julie Elliott, Karen Tanner, Ian McGowan, Angela Kashuba, Peter A Anton, Nicola Richardson-Harman, Craig W Hendrix, Namandjé N Bumpus, Christine Mauck, Ross D Cranston, Kuo Yang, Julie Elliott, Karen Tanner, Ian McGowan, Angela Kashuba, Peter A Anton

Abstract

Objectives: This study was designed to assess the dose-response relationship between tissue, blood, vaginal and rectal compartment concentrations of tenofovir (TFV) and tenofovir diphosphate (TFVdp) and ex vivo rectal HIV suppression following oral tenofovir disoproxil fumarate (TDF) and rectal administration of TFV 1% vaginally-formulated gel.

Design: Phase 1, randomized, two-site (US), double-blind, placebo-controlled study of sexually-abstinent males and females.

Methods: Eighteen participants received a single 300 mg exposure of oral TDF and were then randomized 2∶1 to receive a single then seven-daily rectal exposures of TFV 1% gel (40 mg TFV per 4 ml gel application) or hydroxyethyl-cellulose (HEC) placebo gel. Blood and rectal biopsies were collected for pharmacokinetic TDF and TFVdp analyses and ex vivo HIV-1 challenge.

Results: There was a significant fit for the TFVdp dose-response model for rectal tissue (p = 0.0004), CD4+MMC (p<0.0001), CD4-MMC (p<0.0001), and TotalMMC (p<0.0001) compartments with r2 ranging 0.36-0.64. Higher concentrations of TFVdp corresponded with lower p24, consistent with drug-mediated virus suppression. The single oral treatment failed to provide adequate compartment drug exposure to reach the EC50 of rectal tissue TFVdp predicted to be necessary to suppress HIV in rectal tissue. The EC50 for CD4+MMC was within the single topical treatment range, providing evidence that a 1% topical, vaginally-formulated TFV gel provided in-vivo doses predicted to provide for 50% efficacy in the ex vivo assay. The 7-daily topical TFV gel treatment provided TFVdp concentrations that reached EC90 biopsy efficacy for CD4-MMC, CD4+MMC and TotalMMC compartments.

Conclusion: The TFVdp MMC compartment (CD4+, CD4- and Total) provided the best surrogate for biopsy infectibility and the 7-daily topical TFV gel treatment provided the strongest PK profile for HIV suppression. ClinicalTrials.gov NCT00984971.

Conflict of interest statement

Competing Interests: This analysis was supported by a subcontract with Advanced BioScience Laboratories, Inc., Rockville, MD, and its subcontractor, Alpha StatConsult, LLC, through an NIH/NIAID/DAIDS contract: “Comprehensive Resources for HIV Microbicides and Biomedical Prevention” (#HHSN272201000001C). Co-author Nicola Richardson-Harman is employed by Alpha StatConsult, LLC. Co-author C. Hendrix has had research support from Gilead Sciences from 05/01/09-04/30/10. The contract was managed by the Johns Hopkins School of Medicine. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

Figures

Figure 1. CONSORT flowchart.
Figure 1. CONSORT flowchart.
Figure 2. Study flow diagram.
Figure 2. Study flow diagram.
Paired measures from compartment concentrations (CC) and both CC and biopsy samples (*) taken at the bolded visits: V3 (Visit 3: ∼30 mins post single oral dose), V5 (1–6 days post V3 dose), V6 (7–9 days post V3 dose), V7 (∼30 mins post single topical dose), V9 (1–3 days post V7 dose), V10 (7–12 days post V7 does) and V12 (∼30 mins post 7th daily dose) used in the dose-response analysis.
Figure 3. Tenofovir (TFV) and Tenofovir Diphosphate…
Figure 3. Tenofovir (TFV) and Tenofovir Diphosphate (TFVdp) concentration and biopsy cumulative p24 dose-response relationships.
Results are shown for those CC:p24 paired measurements with detectable concentrations of drug following single oral TDF (), single topical TFV gel (□) and 7-day topical TFV gel (▾) microbicide treatments for the dose-response relationship between CC drug concentrations and ex vivo p24 levels. Figure panels A-D show TFVdp in (A) rectal tissue, (B) TFVdp CD4+ MMC, (C) TFVdp CD4− MMC, (D) TFVdp TotalMMC and (E) Tenofovir (TFV) rectal fluid concentration. Parameters from the log-log non-linear model with a Hill slope factor of –1.0, where r2 and probability levels for the fit of the non-linear least-squares analysis of variance are embedded. Vertical lines indicate the EC50 and EC90 calculated by the logistic regression analysis as the compartmental drug concentrations predicted to provide 50 and 90% efficacy in the explant infectivity assay.

References

    1. Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE Jr, et al. (2005) A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 192: 1545–1556.
    1. Batman PA, Fleming SC, Sedgwick PM, MacDonald TT, Griffin GE (1994) HIV infection of human fetal intestinal explant cultures induces epithelial cell proliferation. AIDS 8: 161–167.
    1. Fischetti L, Barry SM, Hope TJ, Shattock RJ (2009) HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS 23: 319–328.
    1. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, et al. (2000) Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 74: 5577–5586.
    1. Hladik F, Doncel GF (2010) Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res 88 Suppl 1: S3–9.
    1. Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, et al. (2012) RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 28: 1412–1421.
    1. Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, et al. (2011) First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One 6: e23243.
    1. Richardson-Harman N, Mauck C, McGowan I, Anton P (2012) Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses 28: 1422–1433.
    1. Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, et al. (2005) In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21: 845–853.
    1. Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, et al. (2013) MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 8: e55013.
    1. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, et al. (2000) Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 14: 1761–1765.
    1. Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, et al. (2006) Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 20: 1237–1245.
    1. Richardson-Harman N, Lackman-Smith C, Fletcher PS, Anton PA, Bremer JW, et al. (2009) Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol 47: 3530–3539.
    1. Glatting G, Kletting P, Reske SN, Hohl K, Ring C (2007) Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 34: 4285–4292.
    1. Yang K-H. (in prep) A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxyl Fumarate. PloS One.
    1. SAS Institute. The Logistic Procedure. In: SAS/STAT User’s Guide: SAS Institute Inc. (1999) 1903–2042.
    1. Tebit DM, Ndembi N, Weinberg A, Quinones-Mateu ME (2012) Mucosal transmission of human immunodeficiency virus. Curr HIV Res 10: 3–8.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться